Dexmedetomidine and acute kidney injury following cardiac surgery in pediatric patients—An updated systematic review and meta-analysis

Hongbai Wang1 ‡, Chaobin Zhang1 ‡, Yinan Li1, Yuan Jia1, Su Yuan1, Jianhui Wang1 * and Fuxia Yan1 * †

1Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen (Sun Yat-sen Cardiovascular Hospital, Shenzhen), Shenzhen, China

Background: Acute kidney injury (AKI) is a common postoperative complication in pediatric patients undergoing cardiac surgery and associated with poor outcomes. Dexmedetomidine has the pharmacological features of organ protection in cardiac surgery patients. The aim of this meta-analysis is to investigate the effect of dexmedetomidine infusion on the incidence of AKI after cardiac surgery in pediatric patients.

Methods: The databases of Pubmed, Embase, and Cochrane Library were searched until April 24, 2022 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RevMan 5.3 was used to perform statistical analyses.

Results: Five relevant trials with a total of 630 patients were included. The pooled result using fixed-effects model with OR demonstrated significant difference in the incidence of AKI between patients with dexmedetomidine and placebo (OR = 0.49, 95% CI: [0.33, 0.73], I² = 0%, p for effect = 0.0004). Subgroup analyses were performed based on congenital heart disease (CHD) types and dexmedetomidine intervention time. Pooled results did not demonstrate considerable difference in the incidence of AKI in pediatric patients receiving intraoperative (OR = 0.53, 95% CI: [0.29, 0.99], I² = 0%, p for effect = 0.05) or postoperative dexmedetomidine infusion (OR = 0.56, 95% CI: [0.31, 1.04], p for effect = 0.07), but a significant difference in patients receiving combination of intra- and postoperative dexmedetomidine infusion (OR = 0.27, 95% CI: [0.09, 0.77], p for effect = 0.01). Besides, there was no significant difference in duration of mechanical ventilation (SMD: –0.19, 95% CI: –0.46 to 0.08, p for effect = 0.16; SMD: –0.16, 95% CI: –0.37 to 0.06, p for effect = 0.15), length of ICU (SMD: 0.02, 95% CI: –0.41 to 0.44, p for effect = 0.93) and hospital stay (SMD: 0.2, 95% CI: –0.13 to 0.54, p for effect = 0.23), and in-hospital mortality (OR = 1.26, 95% CI: 0.33–4.84, p for effect = 0.73) after surgery according to the pooled results of the secondary outcomes.
Conclusion: Compared to placebo, dexmedetomidine could significantly reduce the postoperative incidence of AKI in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), but the considerable difference was reflected in the pediatric patients receiving combination of intra- and postoperative dexmedetomidine infusion. Besides, there was no significant difference in duration of mechanical ventilation, length of ICU and hospital stay, or in-hospital mortality after surgery.

KEYWORDS
pediatric patients, congenital heart disease, dexmedetomidine, cardiac surgery, cardiopulmonary bypass, acute kidney injury, meta-analysis

Introduction

Acute kidney injury (AKI) is a common postoperative complication in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) due to congenital heart disease (CHD). The incidence of AKI ranges from 20 to 86% depending on different diagnostic tools and medical centers (1). The occurrence of AKI is a risk factor for adverse prognosis, such as prolonged ICU and hospital stay, and increased mortality (2, 3). Studies demonstrated that the elevated reactive oxygen species, hemolysis and systemic inflammatory response induced by CPB have been suggested to be the potential mechanisms developing pediatric AKI after cardiac surgery (4, 5). Additionally, several risk factors of AKI have been identified, such as younger age, complicated cyanotic CHD, perioperative hemodynamic compromise, longer CPB time, fluid overload (6, 7).

Dexmedetomidine is a highly selective α2-adrenergic receptor agonist, and it also has the pharmacological features of sedation, analgesia, systemic circulation stability, and anti-inflammatory response (8). Therefore, dexmedetomidine has the potential effect of nephroprotection in pediatric patients undergoing cardiac surgery. Although dexmedetomidine is still considered as off-label use in pediatric patients, piles of clinical studies on effect of dexmedetomidine on organ protection in children have been completed or are on progress (9, 10). The primary aim of this systematic review and meta-analysis was to investigate the effect of dexmedetomidine infusion on the incidence of AKI after cardiac surgery in pediatric patients by synthesizing the results of previous clinical studies.

Methods

We performed this systematic review and meta-analysis according to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Supplementary Table 1) (11).
Quality assessment of included studies

Two authors independently assessed the quality of included studies. For RCTs, we assessed the risk of bias using the Cochrane Collaboration Risk of Bias Assessment tool, which included the following seven items: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective reporting, and (7) others (bias due to vested financial interest and academic bias) (12). If a trial was found to have one or more of the items associated with high or unclear risk of bias, this trial was classified as high risk. For the observational trials, risk of bias was assessed using the Newcastle–Ottawa Quality Assessment Scale (NOS), which comprises the following three domains: (1) selection, (2) comparability, and (3) outcome for cohort studies (13). There were four stars in the selection domain, two stars in the comparability domain, and three stars in the exposure domain. Trials with seven or more cumulative stars were considered to be of high quality, those with six stars of moderate quality, and those with < 6 stars of low quality. If the two authors disagreed on their assessment, they consulted the third or fourth author. Eventually, we reached a consensus.

Data extraction

Two authors were responsible for extracting the following information: (1) authors; (2) publication year; (3) country of publication; (4) total number of participants in each study; (5) percentage of males; (6) age range of all the participants; (7) weight; (8) procedures that the participants underwent; (9) dose and time points of dexmedetomidine administration; (10) duration of CPB; (11) duration of aortic clamping; (12) assessment time of AKI; (13) number of patients with or without dexmedetomidine; (14) assessment (or follow-up) time; (15) number of patients with and without AKI; (16) postoperative duration of mechanical ventilation; (17) postoperative length of ICU stay; (18) postoperative length of hospital stay; (19) number of dead patients during the follow-up time. Another two authors were responsible for adjusting data discrepancies.

Outcome measures

The primary aim of this meta-analysis was to investigate the effect of dexmedetomidine infusion on the incidence of AKI in pediatric patients undergoing cardiac surgery with CPB. Additionally, we also evaluated the association between dexmedetomidine infusion and duration of mechanical ventilation, length of ICU and hospital stay, and all-cause mortality after surgery as the secondary outcomes.

Data analysis

Review Manager (RevMan) version 5.3 (Cochrane collaboration, Oxford, United Kingdom) was used to perform statistical analyses. We assessed the heterogeneity of included studies using the values of $I^2$ and the Mantel-Haenszel chi-square test ($p$-value for heterogeneity). The values of $I^2 < 40\%$, $I^2 = 40–60\%$, and $I^2 > 60\%$ indicated low, moderate, and high heterogeneity, respectively (14). If we identified $I^2 > 50\%$ or a $p$-value for heterogeneity $< 0.1$, we used a random-effect model to analyze the data. Conversely, if we identified $I^2 < 50\%$ or a $p$-value for heterogeneity $\geq 0.1$, we used a fixed-effect model to analyze the data (15). The continuous outcomes were analyzed using a random-effect model. We transformed the median and range interquartile into mean and standard difference (SD) according to the method from Luo et al. (16) and Wan et al. (17). The dichotomous outcomes were reported as odds ratios (OR) with 95% confidence intervals (CI), while the continuous outcomes as standardized mean difference (SMD) and 95% CI. The statistical tests were two-sided, and overall effects with a $p < 0.05$ were considered to exhibit significant differences.

The subgroup analyses of the primary outcome were performed depending on types of CHD and the infusion time of dexmedetomidine (intraoperative infusion and combination of continuous intraoperative and postoperative infusion).

Results

Study selection

Figure 1 presents the PRISMA flow chart for our screening process. We obtained 11 trials from Pubmed, 10 from Embase, and 11 from Cochrane Library. We removed 15 duplicate trials and excluded 12 trials at the title-and-abstract review stage based on our exclusion criteria. Finally, we enrolled five articles including a total of 630 patients (Figure 1) (18–22).

Study characteristics

There were five trials and 630 patients. Table 1 demonstrated the basic characteristics of the included studies. Of them, four studies were RCTs (18, 19, 21, 22), and one was retrospective observational study (20). Two studies enrolled the pediatric patients undergoing cardiac surgery due to simple and complicated CHD (19, 20). The patients in the other
three studies only underwent repair of ASD or VSD (18, 21, 22). Besides, three articles presented dexmedetomidine infusion intraoperatively (18, 19, 21), and one study extended until 12 after surgery (22), and the retrospective study presented postoperative dexmedetomidine infusion within 24 h after surgery (20). One study assessed the AKI by the method of AKI Network (AKIN) (18), and the others by the method of Kidney Disease Improving Global Outcomes (KDIGO). Three articles reported duration of mechanical ventilation postoperatively (19–21). Two articles presented length of ICU stay following surgery (20, 21). The number of articles provided length of hospital stay (19) and mortality (20) after surgery was only one, respectively.

**Study quality**

We used NOS to assess the risk of bias in observational studies, and the retrospective trial obtained eight stars, indicating high quality (Supplementary Table 2). We used the Cochrane Collaboration Risk of Bias Assessment tool to assess the risk of bias in RCTs. All of included RCTs were high risk of bias, as they clearly assessed random sequence generation four studies-100%), allocation concealment (zero study-0%), blinding of participants (zero study-0%), blinding of outcome assessment (zero study-0%), incomplete outcome data (four studies-100%), and selective outcome reporting (four studies-100%) (Supplementary Figure 1). Four RCTs were found to be low quality due to the possible problems of random allocation and blindness (Supplementary Figure 2).

**Post-operative acute kidney injury**

The assessment (or follow-up) time and the number of patients with cardiac surgery induced AKI for each study were presented in Table 2. We used a fixed-effect model with OR to analyze the effect of dexmedetomidine infusion on the postoperative incidence of AKI in pediatric patients undergoing cardiac surgery with CPB due to low heterogeneity ($I^2 = 0\%$) (Figure 2). The pooled result demonstrated significant differences in incidence of AKI after cardiac surgery between pediatric patients with dexmedetomidine and placebo (OR = 0.49, 95% CI: [0.33, 0.73], $I^2 = 0\%$, p for effect = 0.0004) (Figure 3).


| Author          | Country      | Number of patients | Male, % | Age    | Weight (kg) | Surgical procedures | CPB time (min) | Aortic clamping time (min) | Method of AKI assessment |
|-----------------|--------------|--------------------|---------|--------|-------------|---------------------|----------------|---------------------------|------------------------|
| Jo et al. (18)  | Korea        | 29                 | 62.1    | 1–6 years | 11.45       | Repair of ASD or VSD | 106.5          | 68                        | AKIN                   |
|                 |              |                    |         |        |             | Loading dose: 0.5 µg/kg was infused over 10 min from anesthesia induction |               |                           |                        |
|                 |              |                    |         |        |             | Maintaining dose: 0.5 µg/kg/h to the end of CPB |               |                           |                        |
| Kim et al. (19) | Korea        | 139                | 62.6    | < 7 years | 10.05       | Cardiac surgery with CPB | 145.1          | 87.8                      | KDIGO                  |
|                 |              |                    |         |        |             | Loading dose: 1 µg/kg over 10 min after the induction of anesthesia |               |                           |                        |
|                 |              |                    |         |        |             | Maintaining dose: 1.5 µg/kg/h during surgery, and 1 µg/kg after CPB initiation |               |                           |                        |
| Kwiatkowski et al. (20) | United States | 204                | 57      | < 18 years | 7           | Cardiac surgery with CPB | 121            | 58.5                      | KDIGO                  |
|                 |              |                    |         |        |             | Infusion initiated on any dose or duration within 24 h after surgery |               |                           |                        |
| Ming et al. (21) | China       | 90                 | 57.8    | 1–6 years | 12.7        | Repair of ASD or VSD | 74.6           | 37.7                      | KDIGO                  |
|                 |              |                    |         |        |             | From the onset of anesthesia until the end of the operation: |               |                           |                        |
|                 |              |                    |         |        |             | 1) 0.2µg/kg/h; 2) 0.4µg/kg/h |               |                           |                        |
| Xie et al. (22) | China        | 168                | 48.8    | 1–6 years | __          | Repair of ASD or VSD | 107.02         | 67.35                     | KDIGO                  |
|                 |              |                    |         |        |             | Loading dose: 0.1µg/kg at 15 min before anesthesia induction |               |                           |                        |
|                 |              |                    |         |        |             | Maintaining dose: 0.5 µg/kg/h until 12 h after operation |               |                           |                        |

ASD, atrial septal defect; VSD, ventricular septal defect; CPB, cardiopulmonary bypass; AKI, acute kidney injury; AKIN, acute kidney injury network; KDIGO, Kidney Disease Improving Global Outcomes.
TABLE 2 Follow-up time and number of patients with AKI under different intervention methods.

| Author            | Assessment (or follow-up) time | Number of patients in control group | Number of patients in dexmedetomidine group | Number of patients with AKI in control group | Number of patients with AKI in dexmedetomidine group |
|-------------------|--------------------------------|-------------------------------------|--------------------------------------------|---------------------------------------------|-----------------------------------------------------|
| Jo et al. (18)    | Within 2 days after surgery    | 14                                  | 15                                         | 9                                           | 4                                                   |
| Kim et al. (19)   | Postoperative 1-7 day           | 68                                  | 71                                         | 16                                          | 12                                                  |
| Kwiatkowski et al. (20) | After cardiac surgery      | 102                                 | 102                                        | 36                                          | 24                                                  |
| Ming et al. (21)  | Within 48 h after surgery      | 30                                  | 0.2µg/kg/h: 30                            | 6                                           | 0.2µg/kg/h: 4                                       |
|                   |                                |                                     | 0.4µg/kg/h: 30                            |                                             | 0.4µg/kg/h: 4                                       |
| Xie et al. (22)   | Within 48 h after surgery      | 84                                  | 84                                         | 16                                          | 5                                                   |

AKI, acute kidney injury.

Subgroup analyses were performed according to the types of CHD and dexmedetomidine intervention time. Compared to placebo, dexmedetomidine significantly reduced the postoperative incidence of AKI in children undergoing correction surgery due to AVSD (OR = 0.34, 95% CI: [0.17, 0.67], $I^2 = 0\%$, $p$ for effect = 0.002) or complicated CHD (OR = 0.60, $I^2 = 0\%$, $p$ for effect = 0.002).
95% CI: [0.36, 0.98], $I^2 = 0\%$, $p$ for effect = 0.04) (Figure 4). Additionally, compared to placebo, the pooled results did not demonstrate considerable difference in incidence of AKI after surgery in pediatric patients receiving intraoperative (OR = 0.53, 95% CI: [0.29, 0.99], $I^2 = 0\%$, $p$ for effect = 0.05) or postoperative (OR = 0.56, 95% CI: [0.31, 1.04], $p$ for effect = 0.07) dexmedetomidine infusion, but a significant reduction in AKI occurrence in patients with combination of intra- and postoperative dexmedetomidine infusion (OR = 0.27, 95% CI: [0.09, 0.77], $p$ for effect = 0.01) (Figure 5).

### Figure 4
Subgroup analysis according to CHD types.

### Figure 5
Subgroup analysis according to intervention time (intraoperative, combination of intra- and postoperative, postoperative dexmedetomidine infusion).
Secondary outcomes

The important secondary outcomes of this meta-analysis were presented in Table 3. There was no significant difference in duration of mechanical ventilation (SMD: –0.19, 95% CI: –0.46 to 0.08, \( p \) for effect = 0.16; SMD: –0.16, 95% CI: –0.37 to 0.06, \( p \) for effect = 0.15) (Figure 6), length of ICU (SMD: 0.02, 95% CI: –0.41 to 0.44, \( p \) for effect = 0.93) (Figure 7) and hospital stay (SMD: 0.2, 95% CI: –0.13 to 0.54, \( p \) for effect = 0.23) (Figure 8) or in-hospital mortality (OR = 1.26, 95% CI: 0.33–4.84, \( p \) for effect = 0.73) (Figure 9) after surgery according to the pooled results of secondary outcomes.

Discussion

This meta-analysis included five studies and a total of 630 individuals. Of them, there were four RCTs containing 426 patients, and one retrospective study containing 204 patients. The results demonstrated that compared to placebo, dexmedetomidine infusion could significantly reduce the postoperative incidence of AKI, but the considerable difference was reflected in the pediatric patients receiving combination of intra- and postoperative dexmedetomidine infusion. Besides, there was no significant difference in duration of mechanical ventilation, length of ICU and hospital stay or in-hospital mortality after surgery between dexmedetomidine and placebo groups.

The development of all organs is not yet mature in children, especially newborns, thus they are prone to occurrence of organ dysfunction following cardiac surgery with CPB (23). Currently, there are mainly three methods to assess AKI in children—AKIN, KDIGO, and the Risk, Injury, Failure, Loss, and End-stage renal disease for pediatric use (pRIFLE) (24). In 2012, KDIGO group proposed to establish a common definition of AKI for adults and children by adjusting subtle differences between AKIN, RIFLE, and pRIFLE. The current diagnostic and staging criteria are based on abrupt varieties in serum creatinine (sCr) levels and urine output (UO) as indicators of kidney impairment (25–28). The enrolled studies in this meta-analysis included two methods of AKI assessment—AKIN and KDIGO.

Studies have explored the mechanisms and risk factors of cardiac surgery-induced AKI. Because of poor autonomous regulation ability in pediatric patients, periperaoperative strong systemic circulation fluctuation easily occurs, and associated with acute injury for their original immature organs, such as AKI (29). Besides, systemic inflammatory response induced by cardiac surgery and CPB is also a pivotal mechanism associated with postoperative AKI occurrence in pediatric patients. Large number of inflammatory and proinflammatory factors are released into the blood circulation, and yield kidney inflammation-induced parenchyma impairment, and eventually lead to AKI (30, 31). Recently, some AKI-related biomarkers

### Table 3: Important secondary outcomes of this meta-analysis.

| Author          | Duration of mechanical ventilation | Length of ICU stay | Length of hospital stay | All-cause death |
|-----------------|-----------------------------------|--------------------|-------------------------|----------------|
| Jo et al. (18)  | NA                                | NA                 | NA                      | NA             |
| Kim et al. (19) | 780 (436–1,510) min                | 27 (22–47) h       | 6 (5–9) d               | NA             |
| Kwiatkowski et al. (20) | 1 (0–4) d                           | 1 (0–8) d          | 9 (7–12) d              | 5 (5%)         |
| Ming et al. (21) | 167.17 ± 32.86 min                | 150.20 ± 24.70 min | 150.20 ± 24.70 min      | NA             |
| Xie et al. (22) | NA                                | NA                 | NA                      | NA             |

NA, not applicable; ICU, intensive care unit.
FIGURE 6
Pooled results of postoperative duration of ventilation time between dexmedetomidine and placebo groups [different dexmedetomidine dose 0.2 µg/kg/h (A) and 0.4 µg/kg/h (B) according to the study from Ming et al.].

FIGURE 7
Pooled result of postoperative length of ICU stay between dexmedetomidine and placebo groups.

FIGURE 8
Pooled result of postoperative length of hospital stay between dexmedetomidine and placebo groups.

have been identified, such as urinary liver-type fatty acid binding protein, serum or urinary neutrophil gelatinase-associated lipocalin, serum kidney injury molecule-1, serum cystatin C, and serum albumin. Additionally, the potential risk factors for AKI occurrence in pediatric patients following cardiac surgery included pulmonary hypertension, cyanotic heart disease, univentricular heart, vasopressor use, CPB use, reoperation, sepsis, younger age, lower body weight, lower preoperative sCr levels, higher preoperative estimated glomerular filtration rate, higher Risk Adjustment for Congenital Heart Surgery-1 score, longer surgery time, longer CPB time, longer aortic cross-clamp time, and higher red blood cell transfusion volume. Because
there are so many risk factors for pediatric AKI after pediatric cardiac surgery, it is difficult to reduce the incidence of AKI by controlling all identified risk factors (1, 32, 33).

Dexmedetomidine, a highly selective $\alpha_2$-adrenergic receptor agonist, acts as a hypnotic and sedative agent due to reduced noradrenaline release in central nervous system by mainly activating presynaptic $\alpha_2$ receptors in the locus coeruleus, thus yielding an unconscious state similar to natural sleep (34). Because of the wide presence of $\alpha_2$ receptor in other organs, such as lung and kidney, dexmedetomidine exhibits its pharmacological role in these important organs (35, 36). Animal experiment demonstrated that dexmedetomidine could attenuate renal fibrosis through $\alpha_2$-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia/reperfusion (37). Besides, dexmedetomidine also has the features of anti-inflammation, anti-oxidation and hemodynamic stability (8, 38). Therefore, dexmedetomidine has the potential function of organ protection perioperatively. Although dexmedetomidine is an off-label drug in the pediatric patients, it currently also has been widely used as an adjuvant medication of general anesthesia or postoperative sedative in clinical practice of pediatric patients (39, 40). Furthermore, studies have proved the safety of dexmedetomidine use in patients aged less than 18 years (41, 42). In recent years, some meta-analyses have comprehensively analyzed the effect of dexmedetomidine administration on incidence of AKI in pediatric patients undergoing cardiac surgery (43, 44).

| Study or Subgroup       | Dexmedetomidine Events | Placebo Events | Total Events | Total Weight | Odds Ratio M-H Random 95% CI |
|-------------------------|------------------------|----------------|--------------|--------------|----------------------------|
| Kwiatkowski 2016        | 5                      | 102            | 4            | 102          | 1.26 [0.33, 4.84]           |
| Total (95% CI)          | 102                    | 102            | 102          | 100.0%       | 1.26 [0.33, 4.84]           |
| Total events            | 5                      | 4              |              |              |                            |

FIGURE 9
Pooled result of postoperative all-cause mortality between dexmedetomidine and placebo groups.

Conclusion

Compared to placebo, dexmedetomidine infusion could significantly decrease the incidence of AKI in pediatric patients undergoing cardiac surgery with CPB. But the statistical difference was only presented in the study with combination of intra- and postoperative dexmedetomidine infusion. Besides, there was no significant difference in duration of mechanical ventilation, length of ICU and hospital stay or in-hospital mortality after surgery between dexmedetomidine and placebo groups based on the analyses of the secondary outcomes. However, considering that there are only five articles with small sample size and most of them have higher risk of bias, the pooled result may be unreliable. Because this topic has important clinical implications, the further updated meta-analysis is required to follow the results with the increasing number of relevant studies.
Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Author contributions

HW and CZ independently assessed the quality of included studies and performed the screening process for titles and abstracts. YL and YJ performed the screening process for full texts. SY and YL were responsible for extracting the data. HW, JW, and FY were responsible for adjusting data discrepancies. JW and FY independently assessed the quality of included studies and supervised the whole process and ensured the effectiveness of the meta-analysis. YJ conducted the statistical analysis and made the figures and tables. HW prepared the manuscript. All authors read and approved the submission of the final manuscript.

Acknowledgments

We would like to thank Dr. Yang Wang (Department of Biostatistics, The Chinese Academy of Medical Sciences, Fuwai Hospital, China) for his help with statistical data management.

References

1. Toda Y, Sugimoto K. AKI after pediatric cardiac surgery for congenital heart diseases-recent developments in diagnostic criteria and early diagnosis by biomarkers. J Intensive Care. (2017) 5:49. doi: 10.1186/s40560-017-0198-2
2. Ricci Z, Di Nardo M, Iacoella C, Netto R, Picca S, Cogo P. Pediatric RIFLE for acute kidney injury diagnosis and prognosis for children undergoing cardiac surgery: a single-center prospective observational study. Pediatr Cardiol. (2015) 34:404–8. doi: 10.1007/s00246-013-0662-z
3. Nunes S, Hessey E, Dorais M, Perreault S, Jouvet P, Phan V, et al. Association of pediatric cardiac surgery-associated acute kidney injury with post-discharge healthcare utilization, mortality and kidney outcomes. Pediatr Nephrol. (2021) 36:2865–74. doi: 10.1007/s00467-021-04999-9
4. Gretchen C, Bayar H, Kochanek PM, Ruppert K, Viegas M, Palmer D, et al. Association between hyperoxemia and increased cell-free plasma hemoglobin during cardiopulmonary bypass in infants and children. Pediatr Crit Care Med. (2022) 23:e111–9. doi: 10.1097/PCC.0000000000002814
5. Martiner MJ, Schwinghacker A, Romero T, Roach GD, Belperio JA, Federman MD. Cell saver blood transfusions may be associated with a decrease in inflammation and improved outcome measures in pediatric cardiac surgery patients. Perfusion. (2022) [Online ahead of print]. doi: 10.1177/026765912211078420
6. Lee HJ, Jung JY, Park SW, Song IK, Kim EH, Kim HS, et al. Risk factors of acute kidney injury in children after cardiac surgery. Acta Anaesthesiol Scand. (2018) 62:1374–82. doi: 10.1111/aas.13210
7. Van den Eynde J, Delpierre B, Jacquemyn X, Pardi I, Rothi H, Gewillig M, et al. Risk factors for acute kidney injury after pediatric cardiac surgery: a meta-analysis. Pediatr Nephrol. (2022) 37:509–19. doi: 10.1007/s00467-021-05297-0
8. Liu X, Li Y, Kang L, Wang Q. Recent advances in the clinical value and potential of dexmedetomidine. J Inflamm Res. (2021) 14:7507–27. doi: 10.2147/JIR.S346089
9. Kiski D, Maley E, Schmidt C. Use of dexmedetomidine in pediatric cardiac anesthesia. Curr Opin Anaesthesiol. (2019) 32:334–42. doi: 10.1097/AOC.0000000000000731
10. Baserga M, DuPont TL, Ostrander B, Minton S, Sheffield M, Balch AH, et al. Dexmedetomidine use in infants undergoing cooling due to neonatal encephalopathy (DICE Trial): a randomized controlled trial: background, aims and study protocol. Front Pain Res. (2021) 2:770511. doi: 10.3389/fpain.2021.770511
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
12. Tonin FS, Lopes LA, Rotta I, Bonetti AF, Pontarolo R, Correr CJ, et al. Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions. Int J Clin Pharm. (2019) 41:785–92. doi: 10.1007/s11096-019-00818-2
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z
14. Ariz O, Athanasiou T, Dzuri A. Minimally invasive conduit harvesting: a systematic review. Eur J Cardiothorac Surg. (2006) 29:324–33. doi: 10.1016/j.ejcts.2005.11.032
15. Chen P, Wu X, Wang Z, Li Z, Tian X, Wang J, et al. Effects of levosimendan on mortality in patients undergoing cardiac surgery: a systematic review and meta-analysis. J Card Surg. (2018) 33:322–9. doi: 10.1111/jocs.13716

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.938790/full#supplementary-material
Congenital heart surgery in infants: effects of acute kidney injury on outcomes.

JAMA Pediatr. Krawczeski C, Li S, et al. Kidney outcomes 5 years after pediatric (2017) 24:380–7. doi: 10.1053/j.ackd.2017.09.007

Chronic Kidney Dis. Thorac Cardiovasc Surg. SG, et al. Incidence, risk factors, and outcomes of acute kidney injury after pediatric (2014) 15:463–8. doi: 10.1053/j.can.2001.24983

Cardiothorac Vasc Anesth. J Roth J, Kerr KF , et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury in children undergoing congenital heart surgery: a prospective randomized trial. Medicine. (2017) 96:23989. doi: 10.1097/MD.0000000000002399

18. Jo YY, Kim JY, Lee JY, Choi CH, Chang YJ, Kwak HJ. The effect of intraoperative dexmedetomidine on acute kidney injury after pediatric congenital heart surgery: a prospective randomized trial. Medicine. (2017) 96:67480. doi: 10.1097/MD.0000000000007480

19. Kim EH, Lee JH, Kim HS, Jang YE, Ji SH, Kim WH, et al. Effects of intraoperative dexmedetomidine on the incidence of acute kidney injury in pediatric cardiac surgery patients: a randomized controlled trial. Pediatr Anesth. (2020):30.1132–8. doi: 10.1111/pai.13995

Kwiatkowski DM, Axelrod DM, Sutherland SM, Tesoro TM, Krawczeski CD. Dexmedetomidine is associated with lower incidence of acute kidney injury after congenital heart surgery. Pediatr Crit Care Med. (2016) 17:128–34. doi: 10.1097/CCM.0000000000001398

21. Ming S, Xie Y, Du X, Huang H, Fan Y, Liang Q, et al. Effect of dexmedetomidine on perioperative hemodynamics and organ protection in children with congenital heart disease: a randomized controlled trial. Medicine. (2021) 100:e22398. doi: 10.1097/MD.0000000000002398

22. Xie Y, Jiang W, Cao J, Xie H. Dexmedetomidine attenuates acute kidney injury in children undergoing congenital heart surgery with cardopulmonary bypass by inhibiting the TLR3/NF-κB signaling pathway. Am J Transl Res. (2021) 13:2763–73.

23. Shime N, Kageyama K, Ashida H, Tanaka Y. Application of modified sequential organ failure assessment score in children after cardiac surgery. J Cardiothorac Vasc Anesth. (2016) 39:8762–73. doi: 10.1088/ki.2014.328

24. Thomas ME, Blaine C, Dawney A, Devonald MA, Flouh S, Laing C, et al. The definition of renal injury and its use in pediatric cardiac surgery: a retrospective multicenter study. Crit Care Med. (2019) 47:1493–9. doi: 10.1097/CCM.0000000000003613

25. Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, et al. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med. (2019) 47:1493–9. doi: 10.1097/CCM.0000000000003613

26. Blinder JJ, Goldstein SL, Lee VV , Baycroft A, Fraser CD, Nelson D, et al. Congenital heart surgery in infants: effects of acute kidney injury on outcomes. J Thorac Cardiovasc Surg. (2012) 143:368–74. doi: 10.1016/j.jtcvs.2011.06.021

27. Sutherland SM, Kwiatkowski DM. Acute kidney injury in children. Adv Chronic Kidney Dis. (2017) 24:380–7. doi: 10.1016/jackd.2017.09.007

28. Greenberg JH, Zappitelli M, Devarajan P, Thiessen-Philbrook HR, Krawczeski C, Li S, et al. Kidney outcomes 5 years after pediatric cardiac surgery: the TRIBE-AKI study. JAMA Pediatr. (2016) 170:1071–8. doi: 10.1001/jamapediatrics.2016.1532

29. Fernández S, Santiago MJ, González R, Urbano J, López J, Solana MJ, et al. Hemodynamic impact of the connection to continuous renal replacement therapy in critically ill children. Pediatr Nephrol. (2019) 34:163–8. doi: 10.1007/s00467-018- 4047-7

30. de Fontnouvelle CA, Greenberg JH, Thiessen-Philbrook HR, Zappitelli M, Roth J, Kerr KE, et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury after pediatric cardiac surgery. Ann Thorac Surg. (2017) 104:2072–9. doi: 10.1016/j.athoracsur.2017.04.038

31. Greenberg JH, Whitlock R, Zhang WR, Thiessen-Philbrook HR, Zappitelli M, Devarajan P, et al. Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. Pediatr Nephrol. (2015) 30:1519–27. doi: 10.1007/s00467-015-3088-4

32. Gist KM, Cooper DS, Wrona J, Faubel S, Altmann C, Gao Z, et al. Acute kidney injury biomarkers predict an increase in serummilrinone concentration earlier than serum creatinine-defined acute kidney injury in infants after cardiac surgery. Thor. Drug Monit. (2018) 40:186–94. doi: 10.1097/FTD.0000000000000496

33. Ekure EN, Esezobor CI, Sridhar A, Vasudevan J, Subramanayan R, Cherian KM. Cardiac surgery-associated acute kidney injury in a developing country: prevalence, risk factors and outcome. Saudi J Kidney Dis Transplant. (2015) 26:489–96. doi: 10.4103/1319-2442.157328

34. Virtanen R. Pharmacological profiles of medetomidine and its antagonist, atipamezole. Acta Vet Scand Suppl. (1989) 85:29–37.

35. Celly CS, Atwal OS, McDonell WN, Black WD. Histopathologic alterations induced in the lungs of sheep by use of alpha2-adrenergic receptor agonists. Am J Vet Res. (1999) 60:154–61.

36. Prezeau L, Richman JG, Edwards SW, Limbird LE. The zeta isoform of 14–3–3 proteins interacts with the third intracellular loop of different alpha2-adrenergic receptor subtypes. J Biol Chem. (1999) 274:13462–9. doi: 10.1074/jbc.274.19.3462

37. Li Q, Chen C, Chen X, Han M, Li J. Dexmedetomidine attenuates renal fibrosis via α2-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia/reperfusion. Life Sci. (2018) 207:1–8. doi: 10.1016/j.lfs.2018.05.003

38. Wang Z, Wu J, Hu Z, Luo C, Wang P, Zhang Y, et al. Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting p75ntr-mediated oxidative stress and apoptosis. Oxid. Med Cell Longev. (2020) 2020:5454210. doi: 10.1155/2020/5454210

39. Plambech MZ, Atlahi A. Dexmedetomidine in the pediatric population: a review. Minerva Anestesiol. (2015) 81:320–32.

40. Leow EH, Chan YH, Ng YH, Lim IKR, Nakao M, Lee JH. Prevention of acute kidney injury in children undergoing cardiac surgery: a narrative review. World J Pediatr Congenit Heart Surg. (2018) 9:79–90. doi: 10.1177/2150135317743211

41. Sperotto F, Mondardini MC, Vitale F, Daviemo D, Campagnano E, Ferreiro F, et al. Prolonged sedation in critically ill children: is dexmedetomidine a safe option for younger age? An off-label experience. Minerva Anestesiol. (2019) 85:164–72. doi: 10.23736/S0375-9393.18.13062-9

42. Horvath R, Halbrooks EF , Overman DM, Friedrichsdorf SJ. Efficacy and safety of postoperative dexmedetomidine administration in infants and children undergoing cardiac surgery: a retrospective cohort study. J Pediatr Intensive Care. (2015) 4:138–45. doi: 10.1007/s00305-015-159829

43. Bellos I, Iliopoulos DC, Perrea DN. Pharmacological interventions for the prevention of acute kidney injury after pediatric cardiac surgery: a network meta-analysis. Clin Exp Nephrol. (2019) 23:782–91. doi: 10.1007/s10157-019- 01706-9

44. Li X, Zhang C, Dai D, Liu H, Ge S. Efficacy of dexmedetomidine in prevention of junctional ectopic tachycardia and acute kidney injury after pediatric cardiac surgery: a meta-analysis. Congent Heart Dis. (2018) 13:799–807. doi: 10.1111/chd.12674